SynthesisEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Efficacy of tezepelumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis.
Synthesis in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the efficacy of tezepelumab as an adjunctive treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
methodsPubMed, SCOPUS, Embase, Web of Science, and the Cochrane Library were systematically searched from database inception through January 2026. Eligible studies compared tezepelumab with placebo or reported pre-post treatment outcomes in tezepelumab-treated cohorts. Outcomes included nasal and olfactory symptom measures (nasal congestion, nasal polyp score, olfactory testing, olfactory-related symptoms, and the Sino-Nasal Outcome Test-22 [SNOT-22]), asthma-related measures (pre-bronchodilator forced expiratory volume in 1 s [FEV
resultsFour studies involving 702 participants met the inclusion criteria. Pre-post analyses demonstrated significant improvements following tezepelumab treatment in nasal congestion (mean difference [MD] 1.6859, 95% confidence interval [CI] [1.3882; 1.9836]), olfactory function (standardized mean difference [SMD] - 1.17, 95% CI - 1.39 to - 0.95), SNOT-22 scores (MD 28.6091, 95% CI [15.9241; 41.2940]), and asthma control (ACQ SMD 1.06, 95% CI 0.54-1.57). Both the asthma with nasal polyps and CRSwNP subgroups exhibited consistent symptom improvement. Changes in FEV
conclusionTezepelumab was associated with significant improvements in rhinologic and asthma-related outcomes in patients with CRSwNP. Larger, well-designed randomized controlled trials are warranted to confirm these findings and to define more accurately the long-term therapeutic role of tezepelumab in this population.
Indexed as
Identifiers
42165888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.